Clinical Trial Update: A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This document reports that a Phase III trial of Fruquintinib for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: NSCLC | Phase 3 | Status: COMPLETED